Gedea Biotech raises 1.5 MEUR (16.5 MSEK) in oversubscribed rights issue as registration CL3-2 trial begins
Lund, Sweden, November 15, 2023: Gedea Biotech today announced that it has raised 1.5 MEUR (16,5 MSEK) to initiate and accelerate clinical trial activities supporting pHyph™ applicable for antibiotic free treatment of vaginal infections. The funds will be used to: · Initiate patient recruitment in the recently approved registration CL3-2-study. · Reach upcoming data readout from the CL4 -study to obtain pHyph proof-of-concept for treating vaginal fungal infections. · Perform microbiome analysis from the CL3-study.Vaginal infections affect at least 400 million women worldwide